NCT01061645

Study of MOC31-PE in Antigen Positive Carcinomas

Phase I Study of MOC31-PE in Antigen Positive Carcinomas

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Oslo University Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Immunotoxins (ITs), monoclonal antibodies conjugated to plant or bacterial toxins, have been extensively investigated for their possible use as anti-tumor agents although not in carcinoma patients with minimal residual disease. Various ITs have been tested in early clinical trials and recent studies demonstrate anti-tumor activity of IT treatment in patients with glioblastoma and different solid tumors. Systemic treatment with immunotoxins directed against carefully selected epithelial cell surface molecules may have a potential for eradicating also dormant metastatic tumor cells, as their action is independent of cell proliferation. The effector moieties of the IT used here, the Pseudomonas exotoxin A (PE), inhibits protein synthesis in eukaryotic cells by catalytic inactivation (ribosylation) of elongation factor 2 in the ribosome complex.

Conditions

• Carcinoma

Interventions

Type	Name	Description
DRUG	MOC31-PE	Immunotoxines

Timeline

• Start date: 2010-09-01
• Primary completion: 2012-02-01
• Completion: 2012-02-01
• First posted: 2010-02-03
• Last updated: 2023-05-08

Locations

1 site across 1 country: Norway